Compare · ALT vs JNJ
ALT vs JNJ
Side-by-side comparison of Altimmune Inc. (ALT) and Johnson & Johnson (JNJ): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ALT and JNJ operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- JNJ is the larger of the two at $560.33B, about 1063.2x ALT ($527.0M).
- Over the past year, ALT is down 53.9% and JNJ is up 49.2% - JNJ leads by 103.1 points.
- JNJ has been more active in the news (8 items in the past 4 weeks vs 3 for ALT).
- JNJ has more recent analyst coverage (25 ratings vs 15 for ALT).
- Company
- Altimmune Inc.
- Johnson & Johnson
- Price
- $2.75+1.48%
- $231.54-0.50%
- Market cap
- $527.0M
- $560.33B
- 1M return
- -10.16%
- +4.10%
- 1Y return
- -53.95%
- +49.19%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 3
- 8
- Recent ratings
- 15
- 25
Altimmune Inc.
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing intranasal vaccines, immune modulating therapies, and treatments for liver disease. The company develops AdCOVID, a single-dose intranasal vaccine that is in Phase I clinical trial to protect against COVID-19; T-COVID, an intranasal immune modulating therapeutic candidate, which is in Phase I/II clinical trial to evaluate the potential of T-COVID to prevent clinical worsening in patients with early COVID-19; NasoShield, an anthrax vaccine product candidate that is in a Phase 1b trial; and NasoVAX, a recombinant intranasal vaccine product candidate, which completed Phase IIa clinical trial for the treatment of seasonal and pandemic use. It also focuses on developing ALT-801, a novel peptide-based dual GLP-1/glucagon receptor agonist for the treatment of non-alcoholic steatohepatitis that is in Phase I clinical trial; and HepTcell, an immunotherapeutic product candidate, which is in Phase II clinical trial for patients chronically infected with the hepatitis B virus. Altimmune, Inc. has a collaboration with the University of Alabama at Birmingham for the development of AdCOVID. The company is headquartered in Gaithersburg, Maryland.
Johnson & Johnson
Johnson & Johnson researches and develops, manufactures, and sells a range of products in the health care field worldwide. It operates through three segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; smoking cessation products under the NICORETTE brand; and acid reflux products under the PEPCID brand. This segment also provides women's health products, such as sanitary pads and tampons under the STAYFREE, CAREFREE, and o.b. brands; wound care products comprising adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. The Pharmaceutical segment offers products in various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, and cardiovascular and metabolic diseases. The Medical Devices segment provides electrophysiology products to treat cardiovascular diseases and neurovascular care products to treat hemorrhagic and ischemic stroke; orthopaedics products in support of hips, knees, trauma, spine, sports, and other; advanced and general surgery solutions that focus on breast aesthetics, ear, nose, and throat procedures; and disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery under the ACUVUE brand. The company markets its products to general public, and retail outlets and distributors, as well as distributes directly to wholesalers, hospitals, and health care professionals for prescription use. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.
Latest ALT
- Pemvidutide Demonstrates Significant Metabolic Improvements in Patients with MASH in New 48‑Week IMPACT Phase 2b Data Presented at EASL 2026
- Altimmune to Participate in Upcoming Investor Conferences
- New IMPACT Phase 2b Data Highlight Concurrent Improvements Across Multiple Non-Invasive Markers and qFibrosis-Measured Fibrosis Regression with Pemvidutide in MASH at EASL 2026
- Amendment: SEC Form SCHEDULE 13G/A filed by Altimmune Inc.
- SEC Form S-8 filed by Altimmune Inc.
- SEC Form 10-Q filed by Altimmune Inc.
- Next-Generation GLP-1 Innovation Could Unlock Massive Metabolic Healthcare Market Opportunities
- Altimmune Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Altimmune Announces First Quarter 2026 Financial Results and Business Update
- SEC Form SCHEDULE 13G filed by Altimmune Inc.
Latest JNJ
- Johnson & Johnson to Acquire Firefly Bio, Inc. to Expand Oncology Pipeline with Novel Degrader Antibody Conjugate Platform
- Johnson & Johnson presents new data further reinforcing the role of nipocalimab in lowering the autoantibodies driving Sjögren's disease
- Johnson & Johnson's Phase 3 prostate cancer study shows ERLEADA® (apalutamide) before and after surgery significantly reduces risk of metastasis or death, breaking a decades-long treatment paradigm
- RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) demonstrates prolonged clinical benefit as a first-line treatment for atypical EGFR-mutated non-small cell lung cancer
- New TECVAYLI® (teclistamab-cqyv) data demonstrate superior progression-free and overall survival as early as first relapse in multiple myeloma
- FDA approves label expansion, cementing TREMFYA® as the only IL‑23 inhibitor proven to help stop further joint damage
- Johnson & Johnson to Host Investor Conference Call on Second-Quarter Results
- SEC Form SD filed by Johnson & Johnson
- SEC Form 13F-HR filed by Johnson & Johnson
- CNS Drug Delivery Technologies Are Reshaping Alzheimer's and Biodefense Research